Applied DNA Sciences, Inc. (NASDAQ:APDN) Short Interest Update

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the target of a large increase in short interest in June. As of June 15th, there was short interest totalling 784,200 shares, an increase of 334.9% from the May 31st total of 180,300 shares. Currently, 89.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 671,200 shares, the days-to-cover ratio is currently 1.2 days.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on APDN shares. HC Wainwright lowered their target price on Applied DNA Sciences from $7.00 to $1.50 and set a “buy” rating for the company in a research report on Monday, June 10th. StockNews.com started coverage on Applied DNA Sciences in a research report on Saturday. They set a “sell” rating for the company.

Institutional Trading of Applied DNA Sciences

An institutional investor recently raised its position in Applied DNA Sciences stock. AMH Equity Ltd increased its stake in Applied DNA Sciences, Inc. (NASDAQ:APDN) by 46.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 540,385 shares of the technology company’s stock after buying an additional 170,385 shares during the quarter. AMH Equity Ltd owned about 63.57% of Applied DNA Sciences worth $222,000 as of its most recent SEC filing. 22.22% of the stock is owned by hedge funds and other institutional investors.

Applied DNA Sciences Price Performance

Shares of APDN opened at $0.41 on Friday. The company has a market cap of $400,232.00, a PE ratio of -0.02 and a beta of 0.08. The business has a fifty day moving average of $2.06 and a 200 day moving average of $7.90. Applied DNA Sciences has a 52-week low of $0.37 and a 52-week high of $37.20.

Applied DNA Sciences (NASDAQ:APDN) last issued its quarterly earnings results on Friday, May 10th. The technology company reported ($5.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.60) by ($0.71). The company had revenue of $0.93 million during the quarter, compared to the consensus estimate of $0.90 million. Applied DNA Sciences had a negative return on equity of 306.32% and a negative net margin of 222.33%. As a group, research analysts anticipate that Applied DNA Sciences will post -2.95 earnings per share for the current fiscal year.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.